CD274 and pachyonychia congenita: By impairing MLL1, the epipolythiodioxopiperazine metabolite verticillin A lowers the amount of H3K4me3 in the PD-L1 promoter, transcriptionally hindering PD-L1 expression and enhancing the effectiveness of PD-L1/PD-1 immunotherapy in PC patients [134].